JP2002538183A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002538183A5 JP2002538183A5 JP2000603353A JP2000603353A JP2002538183A5 JP 2002538183 A5 JP2002538183 A5 JP 2002538183A5 JP 2000603353 A JP2000603353 A JP 2000603353A JP 2000603353 A JP2000603353 A JP 2000603353A JP 2002538183 A5 JP2002538183 A5 JP 2002538183A5
- Authority
- JP
- Japan
- Prior art keywords
- gal
- preparation
- another preferred
- glycoforms
- human glycosylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QIGJYVCQYDKYDW-SDOYDPJRSA-N Galactose-α-1,3-galactose Chemical class O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-SDOYDPJRSA-N 0.000 description 4
- 101700016449 GLA Proteins 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
Description
別の好ましいヒトグリコシル化α−Gal A調製物は、好ましくは少なくとも20％、より好ましくは少なくとも50％、最も好ましくは少なくとも70％の２〜４個のシアル酸残基を有するコンプレックスグリカンを含む、多様なα−Gal Aグリコフォームを有する。別の好ましい実施態様においては、多様なグリコフォームを含むヒトグリコシル化α−Gal A調製物は、オリゴ糖電荷を有しており、その値をＺ数で表すと、100以上、好ましくは150以上、より好ましくは170以上である。また別の好ましい実施態様においては、多様なグリコフォームを含むヒトグリコシル化α−Gal A調製物は、平均して少なくとも16〜50％、好ましくは25〜50％、より好ましくは少なくとも30％のグリコフォームがホスホリル化されている。さらに別の実施態様においては、多様なグリコフォームを有する該調製物は、総グリカンの50〜75％、好ましくは、少なくとも60％がシアリル化されている。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/266,014 US6458574B1 (en) | 1996-09-12 | 1999-03-11 | Treatment of a α-galactosidase a deficiency |
| US09/266,014 | 1999-03-11 | ||
| PCT/US2000/006118 WO2000053730A2 (en) | 1999-03-11 | 2000-03-09 | Medical preparations for the treatment of alpha-galactosidase a deficiency |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010215000A Division JP5615648B2 (ja) | 1999-03-11 | 2010-09-27 | α−ガラクトシダーゼＡ欠乏症の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002538183A JP2002538183A (ja) | 2002-11-12 |
| JP2002538183A5 true JP2002538183A5 (ja) | 2006-03-02 |
Family
ID=23012821
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000603353A Pending JP2002538183A (ja) | 1999-03-11 | 2000-03-09 | α−ガラクトシダーゼＡ欠乏症の治療 |
| JP2010215000A Expired - Lifetime JP5615648B2 (ja) | 1999-03-11 | 2010-09-27 | α−ガラクトシダーゼＡ欠乏症の治療 |
| JP2013174418A Expired - Lifetime JP5899169B2 (ja) | 1999-03-11 | 2013-08-26 | α−ガラクトシダーゼＡ欠乏症の治療 |
| JP2014254079A Expired - Lifetime JP6081980B2 (ja) | 1999-03-11 | 2014-12-16 | α−ガラクトシダーゼＡ欠乏症の治療 |
| JP2016200833A Expired - Lifetime JP6346236B2 (ja) | 1999-03-11 | 2016-10-12 | α−ガラクトシダーゼＡ欠乏症の治療 |
| JP2017219734A Expired - Lifetime JP6626071B2 (ja) | 1999-03-11 | 2017-11-15 | α−ガラクトシダーゼＡ欠乏症の治療 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010215000A Expired - Lifetime JP5615648B2 (ja) | 1999-03-11 | 2010-09-27 | α−ガラクトシダーゼＡ欠乏症の治療 |
| JP2013174418A Expired - Lifetime JP5899169B2 (ja) | 1999-03-11 | 2013-08-26 | α−ガラクトシダーゼＡ欠乏症の治療 |
| JP2014254079A Expired - Lifetime JP6081980B2 (ja) | 1999-03-11 | 2014-12-16 | α−ガラクトシダーゼＡ欠乏症の治療 |
| JP2016200833A Expired - Lifetime JP6346236B2 (ja) | 1999-03-11 | 2016-10-12 | α−ガラクトシダーゼＡ欠乏症の治療 |
| JP2017219734A Expired - Lifetime JP6626071B2 (ja) | 1999-03-11 | 2017-11-15 | α−ガラクトシダーゼＡ欠乏症の治療 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US6458574B1 (ja) |
| EP (6) | EP1163349B1 (ja) |
| JP (6) | JP2002538183A (ja) |
| KR (2) | KR100892334B1 (ja) |
| CN (4) | CN100417727C (ja) |
| AT (1) | ATE386808T1 (ja) |
| AU (1) | AU3519400A (ja) |
| CA (3) | CA2365923A1 (ja) |
| CY (3) | CY1107951T1 (ja) |
| DE (1) | DE60038104T2 (ja) |
| DK (3) | DK2314699T3 (ja) |
| ES (3) | ES2634317T3 (ja) |
| HK (3) | HK1043386B (ja) |
| HU (1) | HU228743B1 (ja) |
| IL (2) | IL145381A0 (ja) |
| MX (1) | MXPA01009222A (ja) |
| NO (2) | NO329689B1 (ja) |
| NZ (1) | NZ514077A (ja) |
| PL (1) | PL210833B1 (ja) |
| PT (3) | PT2314699T (ja) |
| RU (1) | RU2248213C2 (ja) |
| WO (1) | WO2000053730A2 (ja) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6458574B1 (en) * | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| US6083725A (en) * | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| IL155588A0 (en) * | 2003-04-27 | 2003-11-23 | Metabogal Ltd | Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby |
| US20050032211A1 (en) * | 1996-09-26 | 2005-02-10 | Metabogal Ltd. | Cell/tissue culturing device, system and method |
| ES2300439T3 (es) * | 2001-04-30 | 2008-06-16 | Zystor Therapeutics , Inc. | Reconocimiento subcelular de proteinas terapeuticas. |
| US20040005309A1 (en) * | 2002-05-29 | 2004-01-08 | Symbiontics, Inc. | Targeted therapeutic proteins |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| EP1503788B1 (en) * | 2002-04-25 | 2011-06-29 | Shire Human Genetic Therapies, Inc. | Treatment of alpha-galactosidase a deficiency |
| WO2006002283A1 (en) * | 2004-06-21 | 2006-01-05 | Medtronic, Inc. | Medical systems and methods for delivering compositions to cells |
| HUE033381T2 (en) | 2003-01-31 | 2017-11-28 | Mount Sinai School Of Medicine Of New York Univ | Combination therapy for the treatment of protein deficiency disorders |
| US7422310B2 (en) * | 2003-04-25 | 2008-09-09 | Hewlett-Packard Development Company, L.P. | Methods and apparatus for selecting image enhancement techniques |
| US20100196345A1 (en) * | 2003-04-27 | 2010-08-05 | Protalix | Production of high mannose proteins in plant culture |
| US7951557B2 (en) | 2003-04-27 | 2011-05-31 | Protalix Ltd. | Human lysosomal proteins from plant cell culture |
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| DE602005020745D1 (de) | 2004-02-10 | 2010-06-02 | Zystor Therapeutics Inc | Saure alpha-glukosidase und fragmente davon |
| US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
| CN1308444C (zh) * | 2005-04-15 | 2007-04-04 | 中国人民解放军军事医学科学院野战输血研究所 | 基因重组α－半乳糖苷酶大批量发酵液的纯化方法 |
| EP3782655A1 (en) | 2005-05-17 | 2021-02-24 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| ES2547726T3 (es) | 2005-11-18 | 2015-10-08 | Tokyo Metropolitan Institute Of Medical Science | Nueva enzima altamente funcional que tiene especificidad de sustrato modificada |
| WO2007086067A1 (en) * | 2006-01-30 | 2007-08-02 | Diagnostic Technologies Ltd. | Method for monitoring tocolytic treatment |
| EP2099523A2 (en) * | 2006-11-13 | 2009-09-16 | ZyStor Therapeutics , Inc. | Methods for treating pompe disease |
| WO2008135991A2 (en) * | 2007-05-07 | 2008-11-13 | Protalix Ltd. | Large scale disposable bioreactor |
| US20100291060A1 (en) * | 2007-08-29 | 2010-11-18 | Shire Human Genetic Therapies, Inc | Subcutaneous administration of alpha-galactosidase a |
| ES2830350T3 (es) | 2008-05-07 | 2021-06-03 | Biomarin Pharm Inc | Péptidos de dirección lisosómica y usos de los mismos |
| US9050276B2 (en) | 2009-06-16 | 2015-06-09 | The Trustees Of Columbia University In The City Of New York | Autism-associated biomarkers and uses thereof |
| ES2569514T3 (es) | 2009-06-17 | 2016-05-11 | Biomarin Pharmaceutical Inc. | Formulaciones para enzimas lisosómicas |
| US9194011B2 (en) | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
| NZ623294A (en) * | 2010-03-02 | 2015-10-30 | Protalix Ltd | Stabilized alpha-galactosidase and uses thereof |
| WO2011133802A1 (en) * | 2010-04-21 | 2011-10-27 | Helix Therapeutics, Inc. | Compositions and methods for treatment of lysosomal storage disorders |
| TR201815211T4 (tr) * | 2010-07-08 | 2018-11-21 | Baxalta GmbH | Hücre kültüründe rekombinant adamts13 üretmeye yönelik yöntem. |
| CN103391784A (zh) | 2010-10-15 | 2013-11-13 | 纽约市哥伦比亚大学理事会 | 肥胖症-相关的基因和它们的蛋白和其用途 |
| PT2635299T (pt) | 2010-11-02 | 2019-10-14 | Univ Columbia | Métodos de tratamento de distúrbios de perda de cabelo |
| RU2597975C2 (ru) * | 2011-03-04 | 2016-09-20 | Глитек, Инк. | Способы получения сахарной цепи, содержащей сиаловую кислоту |
| KR102128248B1 (ko) | 2011-06-08 | 2020-07-01 | 샤이어 휴먼 지네틱 테라피즈 인크. | Mrna 전달을 위한 지질 나노입자 조성물 및 방법 |
| CA2866683A1 (en) | 2012-03-07 | 2013-09-12 | Amicus Therapeutics, Inc. | High concentration alpha-glucosidase compositions for the treatment of pompe disease |
| US10039777B2 (en) | 2012-03-20 | 2018-08-07 | Neuro-Lm Sas | Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders |
| PL2830662T3 (pl) | 2012-03-29 | 2019-02-28 | The Trustees Of Columbia University In The City Of New York | Sposoby leczenia zaburzeń utraty włosów |
| EP2874648A4 (en) | 2012-07-17 | 2015-12-30 | Amicus Therapeutics Inc | CO-FORMULATION OF ALPHA-GALACTOSIDASE A AND 1-DEOXYGALACTONOJIRIMYCIN |
| US10155027B2 (en) | 2012-07-17 | 2018-12-18 | Amicus Therapeutics, Inc. | Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease |
| WO2014016873A1 (en) | 2012-07-26 | 2014-01-30 | Jcr Pharmaceuticals Co., Ltd. | Method for production of recombinant human alpha-galactosidase a |
| JP6226435B2 (ja) * | 2012-07-26 | 2017-11-08 | Ｊｃｒファーマ株式会社 | 組換えヒトα−ガラクトシダーゼＡの製造方法 |
| WO2014120900A1 (en) * | 2013-01-31 | 2014-08-07 | Icahn School Of Medicine At Mount Sinai | Enhanced therapeutic regimens for treating fabry disease |
| AU2014239264A1 (en) | 2013-03-14 | 2015-08-27 | Shire Human Genetic Therapies, Inc. | Quantitative assessment for cap efficiency of messenger RNA |
| BR112015022505A2 (pt) | 2013-03-14 | 2017-10-24 | Shire Human Genetic Therapies | avaliação quantitativa para eficiência do cap de rna mensageiro |
| TWI793159B (zh) * | 2013-10-23 | 2023-02-21 | 美商健臻公司 | 重組醣蛋白及其用途 |
| US9682123B2 (en) | 2013-12-20 | 2017-06-20 | The Trustees Of Columbia University In The City Of New York | Methods of treating metabolic disease |
| CA2940318C (en) * | 2014-03-05 | 2020-09-22 | Ultragenyx Pharmaceutical Inc. | Sialylated glycoprotein compositions and uses thereof |
| EA038986B1 (ru) | 2014-09-30 | 2021-11-18 | Амикус Терапьютикс, Инк. | Высокоактивная кислая альфа-глюкозидаза с повышенным содержанием углеводов |
| CN107567495A (zh) * | 2014-12-22 | 2018-01-09 | 建新公司 | 培养哺乳动物细胞的方法 |
| PT3237621T (pt) | 2014-12-22 | 2023-07-20 | Codexis Inc | Variantes da alfa-galactosidase humana |
| WO2016116966A1 (en) | 2015-01-22 | 2016-07-28 | Jcr Pharmaceuticals Co., Ltd. | Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins |
| US9981021B1 (en) | 2015-04-09 | 2018-05-29 | Kinetiq, Inc. | Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| WO2017044807A2 (en) | 2015-09-09 | 2017-03-16 | The Trustees Of Columbia University In The City Of New York | Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease |
| EA201891507A1 (ru) | 2015-12-30 | 2018-12-28 | Амикус Терапьютикс, Инк. | Кислая альфа-глюкозидаза усиленного действия для лечения болезни помпе |
| US11136597B2 (en) | 2016-02-16 | 2021-10-05 | Yale University | Compositions for enhancing targeted gene editing and methods of use thereof |
| WO2017173060A1 (en) | 2016-03-30 | 2017-10-05 | Amicus Therapeutics, Inc. | Formulations comprising recombinant acid alpha-glucosidase |
| IL295551A (en) * | 2016-03-30 | 2022-10-01 | Amicus Therapeutics Inc | A method for selecting recombinant proteins with a high amount of mannose-6-phosphate |
| NL2017294B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Natural cryptic exon removal by pairs of antisense oligonucleotides. |
| WO2018071814A1 (en) | 2016-10-14 | 2018-04-19 | The Trustees Of Columbia University In The City Of New York | Methods of treating alcohol abuse disorder |
| BR112019007210A2 (pt) * | 2016-10-20 | 2019-08-13 | Sangamo Therapeutics Inc | métodos e composições para o tratamento da doença de fabry |
| JP2020503900A (ja) | 2017-01-10 | 2020-02-06 | アミカス セラピューティックス インコーポレイテッド | ファブリー病の処置のための組換えアルファ−ガラクトシダーゼａ |
| EA202290114A1 (ru) * | 2017-03-30 | 2022-03-29 | Амикус Терапьютикс, Инк. | Способ отбора рекомбинантных белков с высоким содержанием m6p |
| US11708569B2 (en) * | 2018-08-29 | 2023-07-25 | University Of Copenhagen | Modified recombinant lysosomal alpha-galactosidase A and aspartylglucoaminidase having low mannose-6-phosphate and high sialic acid |
| US11427813B2 (en) | 2018-12-20 | 2022-08-30 | Codexis, Inc. | Human alpha-galactosidase variants |
| WO2021005176A1 (en) | 2019-07-09 | 2021-01-14 | Genethon | Treatment of glycogen storage disease (gsd) |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5322158B2 (ja) * | 1974-05-02 | 1978-07-06 | ||
| US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
| EP0159604B1 (en) | 1984-04-09 | 1990-11-07 | Toyo Boseki Kabushiki Kaisha | Sustained-release preparation applicable to mucous membrane in oral cavity |
| US4764376A (en) | 1984-06-18 | 1988-08-16 | Eli Lilly And Company | Method of inhibiting aromatase |
| GB8530631D0 (en) * | 1985-12-12 | 1986-01-22 | Ciba Geigy Ag | Thrombin inhibitors |
| US4764378A (en) | 1986-02-10 | 1988-08-16 | Zetachron, Inc. | Buccal drug dosage form |
| US5272066A (en) * | 1986-03-07 | 1993-12-21 | Massachusetts Institute Of Technology | Synthetic method for enhancing glycoprotein stability |
| US5179023A (en) | 1989-03-24 | 1993-01-12 | Research Corporation Technologies, Inc. | Recombinant α-galactosidase a therapy for Fabry disease |
| EP0463109A4 (en) | 1989-03-24 | 1992-11-19 | Research Corporation Technologies, Inc. | Recombinant alpha-galactosidase, a therapy for fabry disease |
| US5382518A (en) * | 1989-07-13 | 1995-01-17 | Sanofi | Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells |
| US5298400A (en) * | 1989-09-05 | 1994-03-29 | Biotechnology Australia Pty. Ltd. | Polynucleotide constructs for secreted glycosylated plasminogen activator inhibitor-2 (PAI-2) |
| US5697901A (en) * | 1989-12-14 | 1997-12-16 | Elof Eriksson | Gene delivery by microneedle injection |
| US5661132A (en) * | 1989-12-14 | 1997-08-26 | Auragen, Inc. | Wound healing |
| US5401650A (en) * | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| US5356804A (en) | 1990-10-24 | 1994-10-18 | Mount Sinai School Of Medicine Of The City Of New York | Cloning and expression of biologically active human α-galactosidase A |
| ATE156344T1 (de) | 1991-04-25 | 1997-08-15 | Univ Brown Res Found | Implantierbare, biokompatible immunisolator- trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte |
| DE69233690T2 (de) | 1991-07-02 | 2008-01-24 | Nektar Therapeutics, San Carlos | Abgabevorrichtung für nebelförmige Medikamente |
| US5750376A (en) | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
| NZ245015A (en) | 1991-11-05 | 1995-12-21 | Transkaryotic Therapies Inc | Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production |
| US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5858751A (en) | 1992-03-09 | 1999-01-12 | The Regents Of The University Of California | Compositions and methods for producing sialyltransferases |
| WO1993023011A1 (en) | 1992-05-18 | 1993-11-25 | Minnesota Mining And Manufacturing Company | Transmucosal drug delivery device |
| US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| KR100291620B1 (ko) | 1992-09-29 | 2001-10-24 | 추후제출 | 부갑상선호르몬의활성단편의폐를통한전달방법 |
| US5389539A (en) | 1992-11-30 | 1995-02-14 | Massachusetts Institute Of Technology | Purification of heparinase I, II, and III from Flavobacterium heparinum |
| US6329191B1 (en) | 1993-08-30 | 2001-12-11 | Hawaii Biotechnology Group, Inc. | DNA encoding recombinant coffee bean alpha-galactosidase |
| JPH09508783A (ja) * | 1993-09-23 | 1997-09-09 | ニユー・イングランド・バイオレイブス・インコーポレイテツド | 新規なグリコシダーゼの単離及び組成物 |
| DE4339605A1 (de) | 1993-11-20 | 1995-05-24 | Beiersdorf Ag | Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Fettsäurepartialglyceriden |
| US5843015A (en) | 1993-12-28 | 1998-12-01 | Becton Dickinson And Company | Molecules for iontophoretic delivery |
| US5789247A (en) | 1994-04-01 | 1998-08-04 | Ballay; Annick | Expression in non-tumoral human lymphoblastoid lines with an integrative vector |
| FR2718357B1 (fr) | 1994-04-06 | 1997-10-03 | Defarges Alain Moreau | Perfectionnements apportés à un dispositif d'injection par jet sans aiguille. |
| US5834251A (en) * | 1994-12-30 | 1998-11-10 | Alko Group Ltd. | Methods of modifying carbohydrate moieties |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| CA2211417A1 (en) * | 1995-01-30 | 1996-08-08 | New York Blood Center, Inc. | Recombinant .alpha.-galactosidase enzyme |
| US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
| US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| US6566089B1 (en) * | 1996-09-04 | 2003-05-20 | Tularik Inc. | Cell-based drug screens for regulators of gene expression |
| US6458574B1 (en) * | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| US6083725A (en) * | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| ATE286120T1 (de) | 1996-09-13 | 2005-01-15 | Transkaryotic Therapies Inc | Therapie für alpha galactosidase a insuffizienz |
| IL125423A (en) * | 1998-07-20 | 2004-08-31 | Israel State | Alkaline alpha-galactosidase having broad substrate specificity |
| US6749851B2 (en) * | 2001-08-31 | 2004-06-15 | Clearant, Inc. | Methods for sterilizing preparations of digestive enzymes |
-
1999
- 1999-03-11 US US09/266,014 patent/US6458574B1/en not_active Expired - Lifetime
-
2000
- 2000-03-09 EP EP00913825A patent/EP1163349B1/en not_active Expired - Lifetime
- 2000-03-09 CA CA002365923A patent/CA2365923A1/en active Pending
- 2000-03-09 AU AU35194/00A patent/AU3519400A/en not_active Abandoned
- 2000-03-09 NZ NZ514077A patent/NZ514077A/xx not_active IP Right Cessation
- 2000-03-09 CN CNB008073120A patent/CN100417727C/zh not_active Expired - Lifetime
- 2000-03-09 EP EP10180757A patent/EP2287319A1/en not_active Withdrawn
- 2000-03-09 PL PL350658A patent/PL210833B1/pl unknown
- 2000-03-09 HU HU0200467A patent/HU228743B1/hu unknown
- 2000-03-09 EP EP10180768.3A patent/EP2314699B1/en not_active Expired - Lifetime
- 2000-03-09 CN CN201610478912.9A patent/CN106110309A/zh active Pending
- 2000-03-09 ES ES10180768.3T patent/ES2634317T3/es not_active Expired - Lifetime
- 2000-03-09 KR KR1020017011552A patent/KR100892334B1/ko active IP Right Grant
- 2000-03-09 EP EP06025159A patent/EP1820862A3/en not_active Ceased
- 2000-03-09 CN CN201310243356.3A patent/CN103585621B/zh not_active Expired - Lifetime
- 2000-03-09 KR KR1020077019031A patent/KR100961740B1/ko active IP Right Grant
- 2000-03-09 PT PT101807683T patent/PT2314699T/pt unknown
- 2000-03-09 ES ES10152432T patent/ES2391221T3/es not_active Expired - Lifetime
- 2000-03-09 DE DE60038104T patent/DE60038104T2/de not_active Expired - Lifetime
- 2000-03-09 CN CNA2007101482923A patent/CN101219213A/zh not_active Withdrawn
- 2000-03-09 ES ES00913825T patent/ES2300256T3/es not_active Expired - Lifetime
- 2000-03-09 WO PCT/US2000/006118 patent/WO2000053730A2/en active IP Right Grant
- 2000-03-09 DK DK10180768.3T patent/DK2314699T3/en active
- 2000-03-09 CA CA3012663A patent/CA3012663A1/en not_active Expired - Lifetime
- 2000-03-09 DK DK00913825T patent/DK1163349T3/da active
- 2000-03-09 IL IL14538100A patent/IL145381A0/xx unknown
- 2000-03-09 JP JP2000603353A patent/JP2002538183A/ja active Pending
- 2000-03-09 RU RU2001127533/15A patent/RU2248213C2/ru active
- 2000-03-09 DK DK10152432.0T patent/DK2186902T3/da active
- 2000-03-09 EP EP17169335.1A patent/EP3231871A1/en not_active Withdrawn
- 2000-03-09 CA CA2833396A patent/CA2833396C/en not_active Expired - Lifetime
- 2000-03-09 MX MXPA01009222A patent/MXPA01009222A/es active IP Right Grant
- 2000-03-09 PT PT10152432T patent/PT2186902E/pt unknown
- 2000-03-09 PT PT00913825T patent/PT1163349E/pt unknown
- 2000-03-09 AT AT00913825T patent/ATE386808T1/de active
- 2000-03-09 EP EP10152432A patent/EP2186902B1/en not_active Revoked
-
2001
- 2001-09-11 NO NO20014415A patent/NO329689B1/no not_active IP Right Cessation
- 2001-09-11 IL IL145381A patent/IL145381A/en not_active IP Right Cessation
-
2002
- 2002-06-07 US US10/165,060 patent/US20030077806A1/en not_active Abandoned
- 2002-06-10 US US10/165,968 patent/US20030113894A1/en not_active Abandoned
- 2002-06-11 HK HK02104366.6A patent/HK1043386B/zh not_active IP Right Cessation
-
2008
- 2008-05-20 CY CY20081100521T patent/CY1107951T1/el unknown
-
2010
- 2010-09-27 JP JP2010215000A patent/JP5615648B2/ja not_active Expired - Lifetime
- 2010-10-22 NO NO20101493A patent/NO20101493L/no not_active Application Discontinuation
- 2010-11-03 HK HK10110284.2A patent/HK1143833A1/xx not_active IP Right Cessation
- 2010-11-11 US US12/944,688 patent/US20110280856A1/en not_active Abandoned
-
2012
- 2012-08-10 CY CY20121100736T patent/CY1113051T1/el unknown
-
2013
- 2013-08-26 JP JP2013174418A patent/JP5899169B2/ja not_active Expired - Lifetime
-
2014
- 2014-12-16 JP JP2014254079A patent/JP6081980B2/ja not_active Expired - Lifetime
-
2016
- 2016-10-12 JP JP2016200833A patent/JP6346236B2/ja not_active Expired - Lifetime
-
2017
- 2017-07-26 CY CY20171100801T patent/CY1119369T1/el unknown
- 2017-11-15 JP JP2017219734A patent/JP6626071B2/ja not_active Expired - Lifetime
-
2018
- 2018-04-03 HK HK18104453.2A patent/HK1245320A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002538183A5 (ja) | ||
| WO2002080969A1 (fr) | Remedes pour des maladies liees a l'arthrite chronique du nourrisson | |
| WO2000068821A3 (en) | Vertically-threaded processor with multi-dimensional storage | |
| CA2278479A1 (en) | Carbohydrate mixture | |
| WO2004008940A3 (en) | A flexible, torsionable cardiac framework for heart wall actuation of the natural heart | |
| IL101727A0 (en) | The acid sphingomyelinase gene and diagnosis of niemann-pick disease | |
| JP2005509121A5 (ja) | ||
| DE69938257D1 (de) | Interne leitweglenkung durch einen mehrstufigen atm knoten | |
| EP1568285A4 (en) | MEANS TO PREVENT AN INCREASE IN THE BLOOD SUGAR TAIL, MEANS TO PREVENT BODY FAT COLLECTION AND ESTABLISHABLE MATERIAL | |
| CA2299013A1 (en) | Neuropeptide y antagonists | |
| EP1333217A3 (en) | Pipe coupling for a corrugated pipe | |
| WO2003047496A3 (de) | Speicher-vorrichtung zur verbrauchsabhängigen aufnahme von medikamenten | |
| CN209282434U (zh) | 一种pci-e电连接器铁脚和胶芯固定结构 | |
| Pruzanski et al. | Lymphocytotoxic and phagocytotoxic activity in progressive systemic sclerosis | |
| JPS6212359Y2 (ja) | ||
| 刘炯朗 et al. | A Quasi-physical Method for Solving the Scheduling Problem of Space Utilization | |
| 曾高坚 | DEEP CONNECTION BETWEEN CG COEFFICIENTS OF OSP (1, 2) ALGEBRA AND THAT OF SO (3) ALGEBRA | |
| Yuankai | Fifth Generation Filmmakers Advance Towards the Market | |
| Gong et al. | Modeling PCBs air-water mass transfer in the presence of DOCs | |
| Schwalm | Behavior of Special Populations in Fires | |
| Kohn | After Prozac | |
| Purdy | The special reflexive dative in the Old Saxon" Heliand" and" Genesis" | |
| Kurdwanowski | Mrówka na szachownicy | |
| 蔡臻欣 | SCREAMER FOREVER | |
| Dmitriev et al. | The features of the hippocampal structure as a neuroanatomical basis for differences in behavior |